The contemplation of amylose for the delivery of ulcerogenic nonsteroidal anti-inflammatory drugs.

This manuscript proposes an innovative approach to mitigate the gastrointestinal adversities linked with nonsteroidal anti-inflammatory drugs (NSAIDs) by exploiting amylose as a novel drug delivery carrier. The intrinsic attributes of V-amylose, such as its structural uniqueness, biocompatibility and biodegradability, as well as its capacity to form inclusion complexes with diverse drug molecules, are meticulously explored. Through a comprehensive physicochemical analysis of V-amylose and ulcerogenic NSAIDs, the plausibility of amylose as a protective carrier for ulcerogenic NSAIDs to gastrointestinal regions is elucidated.

Anticancer and chemopreventive potential of Morinda citrifolia L. bioactive compounds: A comprehensive update.

Morinda citrifolia L., commonly known as Noni, has a longstanding history in traditional medicine for treating various diseases. Recently, there has been an increased focus on exploring Noni extracts and phytoconstituents, particularly for their effectiveness against cancers such as lung, esophageal, liver, and breast cancer, and their potential in cancer chemoprevention.

Honokiol and its analogues as anticancer compounds: Current mechanistic insights and structure-activity relationship.

Lignans are plant-derived polyphenolic compounds with a plethora of biological applications. Also, regarded as phytoestrogens, the lignans offer a variety of health benefits of which the anti-cancer effects are the most attractive. Honokiol is a lignan isolated from various parts of trees belonging to the genus Magnolia.

Targeted delivery of fenamates with aminated starch.

To develop controlled-release tablets based on aminated starch. Aminated starch was characterized with Fourier transform infrared and x-ray diffraction. Thermogravimetric analysis confirmed the preferential oxidation of crystalline region of starch.

Targeted delivery of flufenamic acid by V-amylose.

Controlled release of flufenamic acid by helical V-amylose to achieve enzyme-responsive, targeted release of the cargo drug. Solid-state cross-polarization magic angle spinning carbon-13 nuclear magnetic resonance (CP/MAS NMR), Fourier transform IR and x-ray diffraction (XRD) analysis validated the entrapment of flufenamic acid inside the helical structure of V-amylose. Scanning electron microscopy (SEM) investigations established the morphology of conjugates in simulated gastric environment (pH 1.

Therapeutic delivery with V-amylose.

The helical structure of V-amylose offering a superior encapsulation affinity compared with the other polysaccharides, especially toward the amphiphilic or hydrophobic molecules; in addition to providing a higher resistance toward enzymatic hydrolysis support its applications as a potential drug delivery vehicle. Mainly, the glycosidic linkages and -CH - groups forming the hydrophobic cavity of V-amylose helix, and the glycosyl hydroxyl groups constituting its hydrophilic periphery promote the loading of a diverse range of molecules via van der Waals forces and hydrogen bonding interactions. These properties enable a high-loading efficiency, targeted delivery, and controlled release of the cargo drug molecules by V-amylose.